2019
Effect of epigenetic modifier-based combinations on efficacy in patients with peripheral T-cell lymphoma (PTCL): Deciphering impact of mutations in epigenetic operations on response.
O'Connor O, Sokol L, Shustov A, Falchi L, Lue J, Montanari F, Amengual J, Sawas A, Deng C, Khan K, Jacobs A, Rada A, Kim H, Soderquist C, Park D, Menezes D. Effect of epigenetic modifier-based combinations on efficacy in patients with peripheral T-cell lymphoma (PTCL): Deciphering impact of mutations in epigenetic operations on response. Journal Of Clinical Oncology 2019, 37: 7565-7565. DOI: 10.1200/jco.2019.37.15_suppl.7565.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaHistone deacetylase inhibitorsPTCL patientsNext-generation sequencingTET2 mutationsPhase 2 studyMajority of patientsPhase 1 studyTreatment-naïve individualsT-cell lymphomaLikelihood of responseClinical trial scenariosR lymphomaTCL patientsExploratory endpointsPreclinical dataEfficacy dataHypomethylating agentR StudyPatientsDeacetylase inhibitorsClinical metricsMarked activityLymphomaEpigenetic drugs
2018
Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL)
Falchi L, Lue J, Montanari F, Marchi E, Amengual J, Sawas A, Deng C, Khan K, Kim H, Atkins L, Rada A, Serge C, O'Connor O. Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL). Blood 2018, 132: 1002. DOI: 10.1182/blood-2018-99-116605.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaAngioimmunoblastic T-cell lymphomaT-cell lymphomaDuration of responseAdverse eventsHypomethylating agentR Peripheral T Cell LymphomaResponse rateMedian DORHigh complete response ratePhase 2Dose-escalation portionG1-2 toxicitiesNausea/vomitingPhase 1 patientsPhase 2 doseComplete response ratePhase 1/2 trialProgression-free survivalOverall response rateTreatment-naïve individualsNon-T-cell lymphomasCancer-testis antigensB-cell lymphomaCombination of AZA